Extensive Product Profile: Understanding Bortlieva 2mg Injection Bortlieva 2mg Injection contains Bortezomib, an advanced, targeted antineoplastic agent belonging to the class of proteasome inhibitors. Manufactured under stringent international quality controls by Allieva Pharma Private Limited, it is globally utilized by hematologists and oncologists as a core component in treating complex hematological malignancies. 1. Clinical Indications & Usage Multiple Myeloma (Previously Treated): Used as monotherapy or in combination with other anti-cancer agents (such as pegylated liposomal doxorubicin or dexamethasone) for adult patients who have relapsed after or failed to respond to at least one prior therapy, or for whom stem cell transplantation is ineligible . Newly Diagnosed Multiple Myeloma: Integrated alongside alkylating agents and corticosteroids (e.g., melphalan and prednisone) as a first-line therapy for patients who are not candidates for high-dose chemotherapy and bone marrow transplantation. 2. Mechanism of Action: How Bortlieva Works Reversible 26S Proteasome Inhibition: It selectively binds to and blocks the chymotrypsin-like activity of the 26S proteasome—the primary cellular enzyme complex responsible for breaking down damaged or misfolded proteins. Disruption of Homeostasis: By preventing targeted protein degradation, it causes an acute, toxic buildup of faulty intracellular proteins. This triggers an overwhelming endoplasmic reticulum stress response. 3. Administration and Dosing Guide Administration Route: Bortlieva 2mg must be administered exclusively by a registered oncology healthcare professional in a clinical or hospital setting. Self-administration is strictly prohibited. Modes of Delivery: It can be delivered either via Subcutaneous (SC) injection (under the skin, typically into the thigh or abdomen) or Intravenous (IV) injection (directly into a vein as a 3 to 5-second bolus). The SC route is often preferred to reduce the risk of peripheral nerve toxicities. Dosing Schedule: Dosing cycles fluctuate widely depending on the underlying indication, patient body surface area and concurrent chemotherapy drugs. A typical cycle involves a twice-weekly regimen for 2 weeks followed by a rest period. Dose adjustments or delays are dynamically managed by the physician based on hematological and neurological tolerability. ⚠️ Safety, Side Effects, and Monitoring Peripheral Neuropathy: May induce new or worsening nerve damage, presenting as tingling, burning sensations, numbness, or pain in the hands and feet. Hematological Toxicities: Frequent cycles can induce transient thrombocytopenia (low platelet count), neutropenia (low white cells), and anemia. Complete Blood Counts (CBC) must be checked before every single dose. Cardiac and Hepatic Risks: Rare instances of congestive heart failure and acute liver enzyme elevations have been documented, requiring regular baseline and ongoing organ function panels. Common Side Effects: Nausea, vomiting, diarrhea, constipation, profound fatigue, pyrexia (fever), reduced appetite (anorexia), headache, and sleep disturbances. 📦 Storage and Handling Specifications Temperature Range: Store the unconstitutioned lyophilized powder vial below 25°C (77°F) in a dry, temperature-controlled facility. Light Sensitivity: Keep the vial enclosed inside its original manufacturer box to shield the active chemical compound from direct light and UV exposure. Reconstituted Solutions: Once mixed with normal saline, the solution should be administered immediately or handled strictly within institutional stability protocols. Keep entirely out of reach of children. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis (COA) Verified Batch-Specific Ledger and Origin Documentation Global Drug Import-Export Compliance RESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled exclusively for international wholesale procurement, institutional buyers, and commercial distribution research. Bortlieva 2mg Injection is a specialized cytotoxic agent available exclusively under strict oncology authorization. It must be dispensed and administered solely under the direct guidance of a registered oncology specialist. Why Choose Primecare Impex? 100% Traceability Cross-Border Regulatory Support Secure Cold-Chain & Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted logistics partner and bulk pharmaceutical 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130
